Zhejiang Hisun Pharmaceutical 관리
관리 기준 확인 2/4
We currently do not have sufficient information about the CEO.
주요 정보
Kevin Xiao
최고 경영자
CN¥869.5k
총 보상
| CEO 급여 비율 | n/a |
| CEO 임기 | 1.1yrs |
| CEO 소유권 | n/a |
| 경영진 평균 재임 기간 | 5.5yrs |
| 이사회 평균 재임 기간 | 데이터 없음 |
최근 관리 업데이트
Recent updates
Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Shares Lagging The Industry But So Is The Business
Sep 26
These 4 Measures Indicate That Zhejiang Hisun Pharmaceutical (SHSE:600267) Is Using Debt Reasonably Well
Apr 30Investors Don't See Light At End Of Zhejiang Hisun Pharmaceutical Co., Ltd.'s (SHSE:600267) Tunnel
Mar 29CEO
Kevin Xiao (55 yo)
1.1yrs
테뉴어
CN¥869,500
보상
Mr. Weihong Xiao, also known as Kevin, has been Chief Executive Officer at Zhejiang Hisun Pharmaceutical Co., Ltd. since October 11, 2023. He served as Chief Operating Officer at 3SBio Inc. since March 201...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chief Executive Officer | 1.1yrs | CN¥869.50k | 데이터 없음 | |
| Senior Vice President | 5.5yrs | CN¥1.13m | 0.018% CN¥ 1.8m | |
| Senior Vice President | 5.5yrs | CN¥1.39m | 0.021% CN¥ 2.1m | |
| Director and Senior Vice President | 5.5yrs | CN¥2.13m | 0.021% CN¥ 2.1m | |
| Secretary of the Board | 7.1yrs | CN¥825.50k | 0.013% CN¥ 1.3m |
5.5yrs
평균 재임 기간
50yo
평균 연령
경험이 풍부한 관리: 600267's management team is seasoned and experienced (5.5 years average tenure).